ADMA Biologics 2025 Q3 Earnings Record Net Income Drives Guidance Hike

ADMA Biologics (ADMA) reported fiscal 2025 Q3 earnings on Nov 5, 2025, with results matching estimates and revenue exceeding expectations. . CEO highlighted operational momentum and strategic milestones, including FDA lot releases and ASCENIV utilization growth, while reaffirming disciplined capital deployment.

Revenue

, . This outperformed analyst estimates and reflects strong demand for its plasma-derived biologics.

Earnings/Net Income

, , . This marked a 14-year high for Q3 net income, underscoring improved profitability.

Price Action

, , .

Post-Earnings Price Action Review

The stock’s immediate post-earnings performance reflected mixed sentiment, . However, , .

CEO Commentary

Adam Grossman emphasized ADMA’s operational milestones, including FDA lot releases for yield-enhanced production batches, which he expects to drive margin expansion through 2026. He also highlighted ASCENIV’s record utilization and positive real-world outcomes, along with constructive payer negotiations for 2026 coverage expansion.

Guidance

. . Long-term, .

Additional News

Recent non-earnings updates include Zacks upgrading ADMA’s rating to “Hold” (Rank #3) amid mixed estimate revisions, , and ADMA BioCenters expanding plasma collection capacity to support product demand. Share repurchase programs and operational efficiency measures were reiterated as part of capital deployment strategies.